Boston Scientific Corporation (BSX) Stake Lifted by Artemis Investment Management LLP

Artemis Investment Management LLP boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 0.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 630,119 shares of the medical equipment provider’s stock after purchasing an additional 3,927 shares during the period. Artemis Investment Management LLP’s holdings in Boston Scientific Corporation were worth $18,377,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Swiss National Bank boosted its holdings in shares of Boston Scientific Corporation by 2.9% in the 2nd quarter. Swiss National Bank now owns 5,584,930 shares of the medical equipment provider’s stock valued at $154,814,000 after acquiring an additional 156,800 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Boston Scientific Corporation by 10.5% in the 2nd quarter. Wells Fargo & Company MN now owns 9,157,768 shares of the medical equipment provider’s stock valued at $253,854,000 after acquiring an additional 867,983 shares during the last quarter. Sit Investment Associates Inc. lifted its stake in shares of Boston Scientific Corporation by 37.8% in the 3rd quarter. Sit Investment Associates Inc. now owns 141,710 shares of the medical equipment provider’s stock valued at $4,134,000 after purchasing an additional 38,855 shares during the period. Los Angeles Capital Management & Equity Research Inc. lifted its stake in shares of Boston Scientific Corporation by 35,016.2% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 3,042,464 shares of the medical equipment provider’s stock valued at $84,337,000 after purchasing an additional 3,033,800 shares during the period. Finally, LS Investment Advisors LLC lifted its stake in shares of Boston Scientific Corporation by 5.8% in the 3rd quarter. LS Investment Advisors LLC now owns 40,621 shares of the medical equipment provider’s stock valued at $1,185,000 after purchasing an additional 2,209 shares during the period. 90.45% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Boston Scientific Corporation (BSX) Stake Lifted by Artemis Investment Management LLP” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/11/12/boston-scientific-corporation-bsx-shares-bought-by-artemis-investment-management-llp.html.

A number of equities analysts have weighed in on BSX shares. Cowen and Company restated a “buy” rating and set a $32.00 price objective (up from $31.00) on shares of Boston Scientific Corporation in a research report on Friday, July 28th. Stifel Nicolaus restated a “buy” rating and set a $32.00 price objective on shares of Boston Scientific Corporation in a research report on Sunday, July 30th. UBS AG reiterated a “buy” rating and issued a $31.00 target price (up from $30.00) on shares of Boston Scientific Corporation in a research report on Tuesday, August 1st. Royal Bank Of Canada reiterated a “buy” rating and issued a $31.00 target price on shares of Boston Scientific Corporation in a research report on Friday, September 1st. Finally, SunTrust Banks, Inc. reiterated a “buy” rating and issued a $34.00 target price on shares of Boston Scientific Corporation in a research report on Monday, October 2nd. One research analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $30.77.

Shares of Boston Scientific Corporation (NYSE BSX) traded down $0.23 during midday trading on Friday, hitting $28.36. 6,526,000 shares of the company’s stock traded hands, compared to its average volume of 6,809,734. The stock has a market cap of $38,943.84, a price-to-earnings ratio of 23.25, a P/E/G ratio of 2.19 and a beta of 1.00. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58. Boston Scientific Corporation has a 52 week low of $19.67 and a 52 week high of $29.93.

Boston Scientific Corporation (NYSE:BSX) last released its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.31. Boston Scientific Corporation had a return on equity of 23.60% and a net margin of 9.55%. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the previous year, the company posted $0.27 EPS. The business’s revenue was up 5.6% on a year-over-year basis. equities research analysts forecast that Boston Scientific Corporation will post 1.25 earnings per share for the current year.

In other news, EVP Michael P. Phalen sold 15,500 shares of the company’s stock in a transaction dated Tuesday, August 29th. The shares were sold at an average price of $26.87, for a total transaction of $416,485.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Timothy A. Pratt sold 10,104 shares of the company’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $27.46, for a total transaction of $277,455.84. Following the transaction, the executive vice president now directly owns 185,742 shares of the company’s stock, valued at approximately $5,100,475.32. The disclosure for this sale can be found here. Insiders sold a total of 508,864 shares of company stock valued at $14,581,669 in the last three months. 0.74% of the stock is currently owned by corporate insiders.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply